0	7	Effects	Effect	NNPS
8	10	of	of	IN
11	26	glucocorticoids	glucocorticoid	NNS
27	29	on	on	IN
30	43	transcription	transcription	NN
44	50	factor	factor	NN
51	61	activation	activation	NN
62	64	in	in	IN
65	70	human	human	JJ
71	81	peripheral	peripheral	JJ
82	87	blood	blood	NN
88	99	mononuclear	mononuclear	JJ
100	105	cells	cell	NNS
105	106	.	.	.

108	123	Glucocorticoids	glucocorticoid	NNS
124	128	have	have	VBP
129	131	an	an	DT
132	142	inhibitory	inhibitory	JJ
143	149	effect	effect	NN
150	152	on	on	IN
153	165	inflammatory	inflammatory	JJ
166	169	and	and	CC
170	176	immune	immune	JJ
177	186	responses	response	NNS
186	187	,	,	,
188	191	and	and	CC
192	196	this	this	DT
197	200	may	may	MD
201	203	be	be	VB
204	211	through	through	IN
212	215	the	the	DT
216	226	modulation	modulation	NN
227	229	of	of	IN
230	243	transcription	transcription	NN
244	250	factor	factor	NN
251	258	binding	bind	VBG
259	261	to	to	TO
262	265	DNA	DNA	NNP
265	266	.	.	.

267	270	The	the	DT
271	282	interaction	interaction	NN
283	285	of	of	IN
286	289	the	the	DT
290	303	transcription	transcription	NN
304	311	factors	factor	NNS
311	312	,	,	,
313	322	activator	activator	NN
323	332	protein-1	protein-1	NN
333	334	(	(	(
334	338	AP-1	ap-1	NN
338	339	)	)	)
339	340	,	,	,
341	348	nuclear	nuclear	JJ
349	355	factor	factor	NN
356	361	kappa	kappa	NN
362	363	B	B	NNP
364	365	(	(	(
365	367	NF	NF	NNP
368	373	kappa	kappa	NNP
374	375	B	B	NNP
375	376	)	)	)
376	377	,	,	,
378	381	and	and	CC
382	397	cAMP-responsive	camp-responsive	JJ
398	405	element	element	NN
406	413	binding	binding	NN
414	421	protein	protein	NN
422	423	(	(	(
423	427	CREB	CREB	NNP
427	428	)	)	)
429	433	with	with	IN
434	437	DNA	DNA	NNP
438	441	and	and	CC
442	456	glucocorticoid	glucocorticoid	NN
457	466	receptors	receptor	NNS
467	468	(	(	(
468	470	GR	GR	NNP
470	471	)	)	)
472	475	was	be	VBD
476	484	analyzed	analyze	VBN
485	487	in	in	IN
488	493	human	human	JJ
494	504	peripheral	peripheral	JJ
505	510	blood	blood	NN
511	522	mononuclear	mononuclear	JJ
523	528	cells	cell	NNS
529	531	by	by	IN
532	535	gel	gel	NN
536	544	mobility	mobility	NN
545	550	shift	shift	NN
551	557	assays	assay	NNS
557	558	.	.	.

559	568	TNF-alpha	TNF-alpha	NNP
568	569	,	,	,
570	574	IL-1	il-1	NN
575	579	beta	beta	NN
580	583	and	and	CC
584	591	phorbol	phorbol	NN
592	601	myristate	myristate	NN
602	609	acetate	acetate	NN
610	611	(	(	(
611	614	PMA	PMA	NNP
614	615	)	)	)
616	625	treatment	treatment	NN
626	635	increased	increase	VBD
636	640	AP-1	ap-1	NN
641	644	and	and	CC
645	647	NF	NF	NNP
648	653	kappa	kappa	NN
654	655	B	B	NNP
656	659	DNA	DNA	NNP
660	667	binding	binding	NN
668	670	by	by	IN
671	673	up	up	RB
674	676	to	to	TO
677	680	200	200	CD
680	681	%	%	NN
682	685	but	but	CC
686	695	decreased	decrease	VBD
696	700	CREB	CREB	NNP
701	708	binding	binding	NN
709	710	(	(	(
710	712	38	38	CD
712	713	%	%	NN
713	714	)	)	)
715	719	over	over	IN
720	721	a	a	DT
722	728	60-min	60-min	JJ
729	733	time	time	NN
734	740	course	course	NN
740	741	.	.	.

742	755	Dexamethasone	Dexamethasone	NNP
756	764	produced	produce	VBD
765	766	a	a	DT
767	772	rapid	rapid	JJ
773	776	and	and	CC
777	786	sustained	sustained	JJ
787	795	increase	increase	NN
796	798	in	in	IN
799	813	glucocorticoid	glucocorticoid	NN
814	822	response	response	NN
823	830	element	element	NN
831	838	binding	binding	NN
839	842	and	and	CC
843	844	a	a	DT
845	856	concomitant	concomitant	JJ
857	862	40-50	40-50	CD
862	863	%	%	NN
864	872	decrease	decrease	NN
873	875	in	in	IN
876	880	AP-1	ap-1	NN
880	881	,	,	,
882	884	NF	NF	NNP
885	890	kappa	kappa	NN
891	892	B	B	NNP
892	893	,	,	,
894	897	and	and	CC
898	902	CREB	CREB	NNP
903	906	DNA	DNA	NNP
907	914	binding	binding	NN
915	919	that	that	WDT
920	923	was	be	VBD
924	931	blocked	block	VBN
932	934	by	by	IN
935	943	combined	combined	JJ
944	957	dexamethasone	dexamethasone	NN
958	961	and	and	CC
962	970	cytokine	cytokine	NN
971	973	or	or	CC
974	977	PMA	PMA	NNP
978	987	treatment	treatment	NN
987	988	.	.	.

989	994	These	these	DT
995	1001	latter	latter	JJ
1002	1009	effects	effect	NNS
1010	1014	were	be	VBD
1015	1018	due	due	JJ
1019	1021	to	to	TO
1022	1031	increases	increase	NNS
1032	1034	in	in	IN
1035	1038	the	the	DT
1039	1046	nuclear	nuclear	JJ
1047	1059	localization	localization	NN
1060	1062	of	of	IN
1063	1065	GR	GR	NNP
1065	1066	,	,	,
1067	1070	not	not	RB
1071	1073	to	to	TO
1074	1081	reduced	reduce	VBN
1082	1089	amounts	amount	NNS
1090	1092	of	of	IN
1093	1096	the	the	DT
1097	1102	other	other	JJ
1103	1116	transcription	transcription	NN
1117	1124	factors	factor	NNS
1124	1125	.	.	.

1126	1130	This	this	DT
1131	1139	suggests	suggest	VBZ
1140	1144	that	that	IN
1145	1147	in	in	IN
1148	1153	these	these	DT
1154	1159	cells	cell	NNS
1160	1162	GR	gr	NN
1163	1169	within	within	IN
1170	1173	the	the	DT
1174	1181	nucleus	nucleus	NN
1182	1191	interacts	interact	VBZ
1192	1196	with	with	IN
1197	1216	cytokine-stimulated	cytokine-stimulated	JJ
1217	1230	transcription	transcription	NN
1231	1238	factors	factor	NNS
1239	1241	by	by	IN
1242	1245	the	the	DT
1246	1253	process	process	NN
1254	1256	of	of	IN
1257	1262	cross	cross	NN
1263	1271	coupling	coupling	NN
1271	1272	.	.	.

1273	1277	This	this	DT
1278	1281	may	may	MD
1282	1284	be	be	VB
1285	1287	an	an	DT
1288	1297	important	important	JJ
1298	1307	molecular	molecular	JJ
1308	1312	site	site	NN
1313	1315	of	of	IN
1316	1323	steroid	steroid	NN
1324	1330	action	action	NN
1330	1331	.	.	.